Roche’s Tecentriq plus chemo shows promise in first-line, advanced bladder cancer
pharmafile | October 1, 2019 | News story | Manufacturing and Production, Research and Development | Cancer, ESMO 2019, Roche, breast cancer, pharma, tecentriq
Roche has revealed data from an interim analysis of its immunotherapy Tecentriq (atezolizumab) at the 2019 European Society for Medical Oncology (ESMO) congress, showing promising performance in combination with platinum-based chemotherapy in the first-line treatment of previously untreated locally advanced or metastatic urothelial carcinoma (mUC) eligible and ineligible for cisplatin chemotherapy.
The Tecentriq combo demonstrated a “statistically significant improvement” in progression-free survival (PFS) of 8.2 months compared to 6.3 months with chemotherapy alone.
In overall survival, Tecentriq was shown to extend life by a median of 16 months compared to 13.4 months with chemo alone, but these data had not achieved statistical significance at this point in the study.
The drug was also tested as a monotherapy, showing “encouraging” overall survival results in patients with high PD-L1 expression, but these data were not formally tested.
“We are pleased with these positive results from the IMvigor130 study, which show Tecentriq plus chemotherapy may provide a meaningful benefit for people newly diagnosed with advanced bladder cancer,” said Dr Sandra Horning, Chief Medical Officer and Head of Global Product Development. “There remains a high unmet need for people with advanced bladder cancer, where chemotherapy alone is the current standard of care. These results reinforce the role of immunotherapy in treating this aggressive disease.”
Matt Fellows
Related Content
Bio-Sourcing and Zerion Pharma receive 1.3m euros in funding for joint breast cancer project
Bio-Sourcing and Zerion Pharma have announced that their collaboration to develop an oral form of …
Biocartis announces breast cancer research collaboration with US Mayo Clinic
Biocartis has announced a research collaboration with Mayo Clinic in the US, aiming to develop …
Novartis receives SMC approval for early breast cancer treatment
Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval …
